cyclosporin A

Ligand id: 1024

Name: cyclosporin A

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: cyclosporin a

Structure and Physico-chemical Properties

2D Structure
No information available.
Summary of Clinical Use
Cyclosporine is a powerful immunosupressant. Its inhibitory action on T-lymphocyte activation is used to circumvent graft rejection following autologous organ and tissue transplant. Across the European Union cyclosporin can be used to treat severe keratitis in adults, and has current orphan designation for 8 indications (click here to link to the EMA's list of orphan designations for cyclosporin).
In July 2017, the EMA recommended granting marketing authorisation in the European Union for Verkazia, an ocular formulation containing cyclosporin for the treatment of children (4yrs- adolescent) with the orphan disease severe vernal keratoconjunctivitis (VKC- a form of chronic eye allergy that can lead to corneal ulcers and loss of sight). Cyclosporin in this form had previously received EMA orphan designation for VKC in 2006.
Mechanism Of Action and Pharmacodynamic Effects
Cyclosporin A must form a complex with its immunophilin 'receptor', cyclophilin A (PPIA), before it is able to bind and inhibit calcineurin [6]. It is the inhibition of the phosphatase activity of calcineurin by this drug-protein complex that results in immunomodulatory actions. The overall effect is inhibition of T-lymphocyte activity, including inhibition of production and release of lymphokines such as interleukin-2.